newsfilter
← Latest News
PR Newswire·

Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida

Phase 2 study is the first approved by the FDA and DEA to test psychedelic therapies in the area of binge eating disorders SAN DIEGO, March 23, 2022 /PRNewswire/ -- Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF) ("Tryp" or the "Company"), a pharmaceutic